A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer

[1]  F. Q. Ribeiro.  The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[2]  S. Piana,et al.  Time to re‐consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma , 2015, International journal of cancer.

[3]  E. Rossi,et al.  Terminology and nomenclature schemes for reporting thyroid cytopathology: An overview. , 2015, Seminars in diagnostic pathology.

[4]  R. Fiocca,et al.  Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections , 2015, Histochemistry and Cell Biology.

[5]  Seon-Yong Jeong,et al.  VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases. , 2015, American journal of clinical pathology.

[6]  Paola Ghiorzo,et al.  Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma , 2014, Oncotarget.

[7]  M. Gulley,et al.  Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma , 2014, Journal of cutaneous pathology.

[8]  M. Trovato,et al.  The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome. , 2014, Thyroid : official journal of the American Thyroid Association.

[9]  T. Cenci,et al.  Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience , 2014, Cancer cytopathology.

[10]  S. Hong,et al.  A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma. , 2014, Human pathology.

[11]  A. von Deimling,et al.  Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. , 2014, Thyroid : official journal of the American Thyroid Association.

[12]  A. Ciarrocchi,et al.  High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. , 2014, The Journal of clinical endocrinology and metabolism.

[13]  U. Camenisch,et al.  Value of immunohistochemistry in the detection of BRAFV600E mutations in fine‐needle aspiration biopsies of papillary thyroid carcinoma , 2014, Cancer cytopathology.

[14]  Guoping He,et al.  Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma. , 2014, Oncology letters.

[15]  G. Di Benedetto,et al.  Thyroid fine-needle aspiration: the relevance of BRAF mutation testing , 2014, Endocrine.

[16]  S. Filetti,et al.  BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice? , 2014, Endocrine.

[17]  P. Miccoli,et al.  The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis , 2014, Endocrine.

[18]  Jae Young Seo,et al.  Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with “suspicious for malignant” cytology alone even when the nodules do not show suspicious US features , 2014, Endocrine.

[19]  M. Fleseriu.  Insight into cardiovascular risk factors in patients with acromegaly , 2014, Endocrine.

[20]  M. Schlaak,et al.  Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations , 2014, BMC Cancer.

[21]  F. Deng,et al.  Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. , 2013, Surgery.

[22]  S. Hong,et al.  Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. , 2013, Thyroid : official journal of the American Thyroid Association.

[23]  L. Orloff,et al.  Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. , 2013, JAMA otolaryngology-- head & neck surgery.

[24]  Yong-Wha Lee.  Peptide nucleic acid clamp polymerase chain reaction reveals a deletion mutation of the BRAF gene in papillary thyroid carcinoma: A case report , 2013, Experimental and therapeutic medicine.

[25]  T. Grogan,et al.  Mutation‐specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas , 2013, Cancer.

[26]  S. Hong,et al.  Detection of BRAF V600E mutation with thyroid tissue using pyrosequencing: comparison with PNA-clamping and real-time PCR. , 2013, American Journal of Clinical Pathology.

[27]  S. Piana,et al.  Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. , 2013, The Journal of clinical endocrinology and metabolism.

[28]  L. Sciacca,et al.  Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. , 2013, The Journal of clinical endocrinology and metabolism.

[29]  Y. Kim,et al.  BRAFV600E Mutation Analysis in Papillary Thyroid Carcinomas by Peptide Nucleic Acid Clamp Real-time PCR , 2013, Annals of Surgical Oncology.

[30]  A. Ballestrero,et al.  Molecular characterization of an Italian series of sporadic GISTs , 2013, Gastric Cancer.

[31]  M. Zeiger,et al.  BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. , 2012, The Journal of clinical endocrinology and metabolism.

[32]  J. Bishop,et al.  BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment: A Systematic Review and Meta-Analysis , 2012, Medicine.

[33]  S. Piana,et al.  BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. , 2012, The Journal of clinical endocrinology and metabolism.

[34]  A. von Deimling,et al.  Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma , 2012, The American journal of surgical pathology.

[35]  P. Snijders,et al.  KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. , 2012, The Journal of molecular diagnostics : JMD.

[36]  C. Ki,et al.  Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. , 2012, The Journal of clinical endocrinology and metabolism.

[37]  H. Azizlerli,et al.  BRAFV600E mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness , 2012, Endocrine.

[38]  Shereen Ezzat,et al.  Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. , 2012, The Journal of clinical endocrinology and metabolism.

[39]  V. Marotta,et al.  The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.

[40]  T. Fahey.  Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA Samples , 2012 .

[41]  D. Capper,et al.  Utilization of a MAB for BRAFV 600 E detection in papillary thyroid carcinoma , 2012 .

[42]  M. Zeiger,et al.  BRAF V 600 E mutation and Its Association with Clinicopathological Features of Papillary Thyroid Cancer : A Meta-Analysis , 2012 .

[43]  P. Conesa‐Zamora,et al.  Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E. , 2011, The Journal of molecular diagnostics : JMD.

[44]  H. Zentgraf,et al.  Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody , 2011, Acta Neuropathologica.

[45]  M. Ilyas,et al.  Comparative analysis of pyrosequencing and QMC‐PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection , 2010, International journal of experimental pathology.

[46]  A. Bozec,et al.  Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications. , 2010, Current medicinal chemistry.

[47]  D. Ball.  Selectively targeting mutant BRAF in thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[48]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[49]  E. Mazzaferri.  What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)? , 2009, Oncology.

[50]  M. Santoro,et al.  Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[51]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[52]  A. Goldstein,et al.  Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. , 2006, Human molecular genetics.

[53]  A. Pinchera,et al.  Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. , 2006, Endocrine-related cancer.

[54]  A. Miyauchi,et al.  Papillary Microcarcinomas of the Thyroid with Preoperatively Detectable Lymph Node Metastasis Show Significantly Higher Aggressive Characteristics on Immunohistochemical Examination , 2005, Oncology.

[55]  M. Denis,et al.  Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. , 2004, Molecular and cellular probes.

[56]  P. Ladenson,et al.  Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. , 2004, The Journal of clinical endocrinology and metabolism.

[57]  M. Cowan,et al.  Bone Marrow Transplantation for &bgr;-Thalassemia: The University of California San Francisco Experience , 2000, Journal of pediatric hematology/oncology.

[58]  D. C. Henckel,et al.  Case report. , 1995, Journal.